Final results of the phase I study in healthy volunteers of AB928, a dual antagonist of the A2aR and A2bR adenosine receptors being studied as an activator of anti-tumor immune response

Authors :: D. Ashok
Joyson Joseph Karakunnel
M.J. Walters
A. Park
J. Powers
Manmohan Reddy Leleti
E. Sharif
Brandon Reid Rosen
Ulrike Schindler
Steve Young
Lixia Jin
Aimee Rieger
L.C. Seitz
D. Miles
Source :: Annals of Oncology. 29:viii665
Publication Year :: 2018
Publisher :: Elsevier BV, 2018.

Subjects :: Antitumor activity
Immune system
Oncology
Activator (genetics)
business.industry
Healthy volunteers
Antagonist
Medicine
Hematology
Pharmacology
business
Adenosine receptor
Phase i study

Full Text Access

Tools